When was Accropeutics founded?

Accropeutics was founded in 2017 and raised its 1st funding round 8 years after it was founded.

Where is Accropeutics located?

Accropeutics is headquartered in Suzhou, China.

Who is the current CEO of Accropeutics?

Xiaohu Zhang of Accropeutics. They have also founded 1 company.

How many employees does Accropeutics have?

As of Jun 30, 2026, the latest employee count at Accropeutics is 3.

Is Accropeutics a funded company?

Accropeutics is a funded company, having raised a total of $62M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 14, 2025.

When was the latest funding round of Accropeutics?

Accropeutics' latest funding was a $***** Series C round on May 18, 2026, with participation from 6 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does Accropeutics rank among its competitors?

Accropeutics ranks 278th amongst 3677 active competitors, of which 1238 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Accropeutics?

Accropeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Accropeutics - 2026 Company Profile, Team, Funding & Competitors

Accropeutics is a series C company based in Suzhou (China), founded in 2017 by Xiaohu Zhang and Sudan He. It operates as a Developer of drugs for inflammation, autoimmune diseases, and cancer. Accropeutics has raised $62M in funding from Orbimed and Shenzhen Capital Group. The company has 3677 active competitors, including 1238 funded and 871 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.

Website: www.accropeutics.com/
Social
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Suzhou, China

Stage

Series C

Total Funding

$62M in 2 rounds

Latest Funding Round

Series C, May 18, 2026, $*****

Investors

Orbimed & 8 more

Ranked

278^th among 3677 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3454 more

View Accropeutics' full profile

Accropeutics has raised a total funding of $62M over 2 rounds. Its first funding round was on Mar 14, 2025. Its latest funding round was a Series C round on May 18, 2026 for $*****. 6 investors participated in its latest round. Accropeutics has 9 institutional investors.

Here is the list of recent funding rounds of Accropeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 18, 2026	4802179	Series C	3211743	1764011	5324698	9707730
Mar 14, 2025	9664324	Series B	7014446	9271684	Shenzhen Capital Group	Morningside & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Accropeutics's funding rounds and investors

The founders of Accropeutics are Xiaohu Zhang and Sudan He. Xiaohu Zhang is the CEO of Accropeutics.

Here are the details of Accropeutics' key team members:

Xiaohu Zhang: Co-Founder & CEO of Accropeutics and founder of 1 other company.
Sudan He: Co-Founder of Accropeutics and founder of 1 other company.

View details of Accropeutics's Founder profiles and Board Members

Accropeutics' employee count trend

Accropeutics has 3 employees as of Jun 26. Here is Accropeutics's employee count trend over the years:

Uncover Accropeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Accropeutics include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Accropeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
278th	Accropeutics 2017, Suzhou (China), Series C	Developer of drugs for inflammation, autoimmune diseases, and cancer	$62M	TCG Crossover, Orbimed & 7 others	58/100